Lymphoma & Plasma Cell Disorders
Conference Coverage
Armored CAR T cells elicit responses in NHL patients
NATIONAL HARBOR, MD. – ICTCAR014, a dominant negative PD-1 armored CAR T-cell therapy, produced responses in 12 of 13 non-Hodgkin lymphoma...
From the Journals
Survival ‘excellent’ after rituximab-bendamustine induction in transplant-eligible MCL
Investigators reported that the regimen’s efficacy is on par with R-hyperCVAD, but is less toxic.
From the Journals
Levofloxacin prophylaxis improves survival in newly diagnosed myeloma
Levofloxacin looks like a promising addition to therapy, but the researchers cautioned that antibiotic resistance must be considered.
Conference Coverage
Consider renal function in TLS risk assessment of venetoclax-treated CLL
EDINBURGH – Impaired renal function may indicate excess risk of tumor lysis syndrome (TLS) in venetoclax-treated...
News
FDA proposes new breast implant labeling with a boxed warning
Following a high-profile hearing in March 2019, and a textured breast implant recall in July, the FDA has proposed a boxed warning and other...
From the Journals
SEER analysis reveals medication adherence factors in newly diagnosed myeloma
The study found that more than a third of older patients with multiple myeloma had poor adherence to lenalidomide.
From the Journals
Pembrolizumab shows promise for relapsed/refractory PMBCL
The findings raise the question of whether PD-1 blockade could resensitize tumors to chemotherapy.
Feature
ASCO to award $50,000 young investigator grant to study MCL
The award is a 1-year grant of $50,000 to pursue clinical research on mantle cell lymphoma.
From the Journals
Vitamin D deficiency appears to worsen survival in Hodgkin lymphoma
The researchers said vitamin D deficiency screening and replacement should be incorporated into future randomized clinical trials of Hodgkin...
From the Journals
Ibrutinib linked to hypertension in B-cell malignancies
New or worsening hypertension was also linked with a greater risk of major adverse cardiac events.
From the Journals
Best treatment approach for early stage follicular lymphoma is unclear
Overall survival rates were similar with different treatment approaches, including watchful waiting.